CA1139662A - Simethicone antacid tablet - Google Patents
Simethicone antacid tabletInfo
- Publication number
- CA1139662A CA1139662A CA000335613A CA335613A CA1139662A CA 1139662 A CA1139662 A CA 1139662A CA 000335613 A CA000335613 A CA 000335613A CA 335613 A CA335613 A CA 335613A CA 1139662 A CA1139662 A CA 1139662A
- Authority
- CA
- Canada
- Prior art keywords
- simethicone
- tablet
- antacid
- volume portion
- inner core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940083037 simethicone Drugs 0.000 title claims abstract description 95
- 229940069428 antacid Drugs 0.000 title claims abstract description 49
- 239000003159 antacid agent Substances 0.000 title claims abstract description 49
- 230000001458 anti-acid effect Effects 0.000 title claims abstract description 47
- -1 Simethicone antacid Chemical class 0.000 title abstract description 6
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 claims abstract description 89
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 45
- 239000004615 ingredient Substances 0.000 claims abstract description 30
- 230000004888 barrier function Effects 0.000 claims abstract description 29
- 230000003254 anti-foaming effect Effects 0.000 claims abstract description 21
- 239000011159 matrix material Substances 0.000 claims abstract description 21
- 230000015556 catabolic process Effects 0.000 claims abstract description 9
- 230000005012 migration Effects 0.000 claims abstract description 5
- 238000013508 migration Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 8
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 description 41
- 239000008101 lactose Substances 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000000576 coating method Methods 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000012876 carrier material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002985 plastic film Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007942 layered tablet Substances 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 229920006255 plastic film Polymers 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VHEMBTYWURNBQQ-UHFFFAOYSA-N butanoic acid;phthalic acid Chemical compound CCCC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O VHEMBTYWURNBQQ-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000007864 suspending Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US007,887 | 1979-01-31 | ||
| US06/007,887 US4198390A (en) | 1979-01-31 | 1979-01-31 | Simethicone antacid tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1139662A true CA1139662A (en) | 1983-01-18 |
Family
ID=21728641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000335613A Expired CA1139662A (en) | 1979-01-31 | 1979-09-14 | Simethicone antacid tablet |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4198390A (https=) |
| EP (1) | EP0014253B1 (https=) |
| JP (1) | JPS55102513A (https=) |
| AU (1) | AU523095B2 (https=) |
| CA (1) | CA1139662A (https=) |
| DE (1) | DE2967263D1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4396604A (en) * | 1982-05-17 | 1983-08-02 | Norcliff Thayer, Inc. | Simethicone antacid lozenge |
| US4518433A (en) * | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
| GB8830407D0 (en) * | 1988-12-30 | 1989-03-01 | Embil Koral | Pharmaceutical formulations |
| US6482516B1 (en) * | 1993-07-20 | 2002-11-19 | Banner Pharmacaps, Inc. | Enrobed tablet |
| DE69116989D1 (de) * | 1990-06-28 | 1996-03-21 | Edko Trading Representation | Mehrphasige pharmazeutische Zusammensetzungen |
| US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
| GR1002332B (el) * | 1992-05-21 | 1996-05-16 | Mcneil-Ppc Inc. | Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη. |
| CA2110313C (en) * | 1992-12-01 | 2004-10-26 | Edward John Roche | Pharmaceutical compositions containing a guanidinothiazole compound and antacids |
| CA2150463A1 (en) * | 1992-12-02 | 1994-06-09 | Donald F. H. Wallach | Extended duration antacid product |
| WO1996004128A1 (de) * | 1994-08-03 | 1996-02-15 | Voss Gunter M | Verfahren zur herstellung von manteltabletten |
| JP3001440B2 (ja) * | 1996-11-25 | 2000-01-24 | 日本電気通信システム株式会社 | 仮想ｌａｎ方式 |
| US5846567A (en) * | 1997-04-16 | 1998-12-08 | Chek-Med Systems, Inc. | Clot dissolving method |
| EP1057472B1 (en) * | 1997-12-03 | 2006-07-26 | Kao Corporation | Solid preparation for oral hygiene |
| FR2774906B1 (fr) * | 1998-02-13 | 2000-05-12 | Rhodia Chimie Sa | Systeme d'encapsulation a coeur organique et a ecorce minerale a base d'hydroxycarbonate d'aluminium et son procede de preparation |
| US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| CA2461616A1 (en) * | 2001-09-28 | 2003-04-03 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US7807197B2 (en) * | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
| US8673352B2 (en) * | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| US20110027356A1 (en) * | 2008-01-25 | 2011-02-03 | Duo-Ge | Combination of Oral Medicaments Bonded by a Wrapping |
| BRPI0918492A2 (pt) | 2008-09-09 | 2015-12-01 | Astrazeneca Ab | uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo |
| AU2010266026B2 (en) * | 2009-06-25 | 2014-08-07 | Nuvo Pharmaceuticals (Ireland) Designated Activity Company | Method for treating a patient in need of aspirin therapy |
| EP2445499A4 (en) | 2009-06-25 | 2013-02-27 | Astrazeneca Ab | METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| UA115139C2 (uk) | 2011-12-28 | 2017-09-25 | Поузен Інк. | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту |
| US20140371174A1 (en) | 2013-06-12 | 2014-12-18 | The Procter & Gamble Company | Effervescent Dosage Form |
| CN104363897A (zh) | 2012-06-12 | 2015-02-18 | 宝洁公司 | 泡腾剂型 |
| EP3294269A1 (en) | 2015-06-12 | 2018-03-21 | Santa Farma Ilaç Sanayi A.S. | Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics |
| KR20230137362A (ko) | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| EP4422607A4 (en) | 2021-10-25 | 2025-09-03 | Aquestive Therapeutics Inc | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT |
| CN116139165B (zh) * | 2023-02-13 | 2024-10-01 | 南京艾德加生物制药科技有限公司 | 铝镁西甲硅油咀嚼片及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US462990A (en) * | 1891-11-10 | William oppenheimek | ||
| US2512192A (en) * | 1948-05-26 | 1950-06-20 | American Cyanamid Co | Silicone resin medicament coating |
| US3048526A (en) * | 1958-08-04 | 1962-08-07 | Wander Company | Medicinal tablet |
| US3422189A (en) * | 1959-01-02 | 1969-01-14 | Moraine Products | Method and compositions for the treatment of gastro-intestinal disorders |
| US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
| GB971486A (en) * | 1960-04-01 | 1964-09-30 | Rech S Pharma Et Scient | Therapeutic compositions comprising aspirin and polysiloxanes |
| USRE25205E (en) | 1960-10-10 | 1962-07-24 | Silicone composition for the relief of | |
| AU407324B2 (en) * | 1962-05-01 | 1970-10-28 | Smith, Kline & French Laboratories | Powdered silicone products and processes |
| US3501571A (en) * | 1965-12-06 | 1970-03-17 | Smithkline Corp | Novel silicone compositions and method of preparing same |
| US3567819A (en) * | 1969-01-30 | 1971-03-02 | Hoffmann La Roche | Cold tablet |
| US3767794A (en) * | 1969-11-21 | 1973-10-23 | Richardson Merrell Inc | Antifoam preparations and method of preparing same |
| FR2077913A1 (en) * | 1970-02-24 | 1971-11-05 | Sogeras | Tablets contg gelatine capsules - for administration of liquid medicaments |
| US4127650A (en) * | 1975-03-31 | 1978-11-28 | William H. Rorer, Inc. | Medicinal simethicone containing composition and its method of production |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
-
1979
- 1979-01-31 US US06/007,887 patent/US4198390A/en not_active Expired - Lifetime
- 1979-09-14 CA CA000335613A patent/CA1139662A/en not_active Expired
- 1979-09-21 AU AU51057/79A patent/AU523095B2/en not_active Ceased
- 1979-10-05 JP JP12935179A patent/JPS55102513A/ja active Granted
- 1979-12-14 DE DE7979105188T patent/DE2967263D1/de not_active Expired
- 1979-12-14 EP EP79105188A patent/EP0014253B1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS643845B2 (https=) | 1989-01-23 |
| US4198390A (en) | 1980-04-15 |
| AU5105779A (en) | 1980-08-07 |
| JPS55102513A (en) | 1980-08-05 |
| EP0014253B1 (en) | 1984-10-17 |
| AU523095B2 (en) | 1982-07-08 |
| EP0014253A3 (en) | 1981-01-28 |
| DE2967263D1 (en) | 1984-11-22 |
| EP0014253A2 (en) | 1980-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1139662A (en) | Simethicone antacid tablet | |
| EP0235718B1 (en) | Granule remaining in stomach | |
| CA2294744C (en) | Multiple unit effervescent dosage form | |
| DE2510620C2 (de) | Festes, zum Einnehmen bestimmtes, im Magensaft schwimmfähiges Arzneimittel | |
| US5093200A (en) | Multilayer sustained release granule | |
| US5178868A (en) | Dosage form | |
| US4851226A (en) | Chewable medicament tablet containing means for taste masking | |
| EP0171457B1 (en) | Composition for the controlled discharge of an active ingredient, and its preparation | |
| AU623349B2 (en) | Plurality of tiny pills in liquid dosage form | |
| US3835221A (en) | Orally administrable drug dosage form having delayed action | |
| US4627851A (en) | Colonic-therapeutic delivery system | |
| EP0683666B1 (en) | Water based beverages | |
| US3922338A (en) | Tablets containing in their mass controlled-release micro-capsules and process for manufacture of said tablets | |
| US4876094A (en) | Controlled release liquid dosage formulation | |
| DE19648576C2 (de) | Lutschtablette zur modifizierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt | |
| JPH08506802A (ja) | 波状粒薬配給システム | |
| HU214576B (hu) | Eljárás elnyújtott hatóanyag-leadású, többegységes, többrétegű bevonattal ellátott orális gyógyszerkészítmény előállítására | |
| CA1336069C (en) | Chewable medicament tablet containing means for taste masking | |
| CA2000932C (en) | Oral pharmaceutical controlled release multiple unit dosage form | |
| US4025613A (en) | Timed-release aspirin | |
| CA1157376A (en) | Pharmaceutical compositions containing paracetamol | |
| DE602004006763T2 (de) | Darreichungsform zur kontrollierten Freisetzung einer Formulierung mit aktivem Mittel und Verfahren zur Herstellung der Darreichungsform | |
| AU687420B2 (en) | Soft-shelled gelatin encapsulated particles | |
| JP3343144B2 (ja) | マイクロカプセル | |
| EP2043598A1 (en) | Extended release perforated tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |